Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Glioma × Drug Tolerance × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Multiple Myeloma 1 Glioma 1 Diffuse Intrinsic Pontine Glioma 1 Brain Neoplasms 1

Interventions

Temozolomide 140 Bevacizumab 63 Radiotherapy 54 Magnetic Resonance Spectroscopy 52 Irinotecan 27 Carboplatin 23 Surgical Procedures, Operative 18 Radiation 18 Carmustine 18 Specimen Handling 17 Nivolumab 16 Lomustine 15 Biopsy 15 Aminolevulinic Acid 15 pembrolizumab 12 Radiotherapy, Intensity-Modulated 12 Cyclophosphamide 12 trametinib 11 Topotecan 11 Radiosurgery 11 Erlotinib Hydrochloride 11 fluorodopa F 18 9 IL13-PE38 9 Everolimus 9 ribociclib 8 dabrafenib 8 X-Rays 8 Imatinib Mesylate 8 Filgrastim 8 Etoposide 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04771897 2024-12-20

KONQUER

Bexion Pharmaceuticals, Inc.

Phase 1 Terminated

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡